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Abstract 
Background: The Global Registry of Acute Coronary Events (GRACE) risk score is widely recommended for risk assess‑
ment in patients with acute coronary syndrome (ACS). Chronic hyperglycemia [hemoglobinA1c (HbA1c)] can inde‑
pendently predict major adverse cardiac events (MACEs) in patients with ACS. We investigated whether the prediction 
of MACEs with the GRACE score could be improved with the addition of HbA1c content in ACS patients without 
diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI).
Methods: We enrolled 549 ACS patients without DM who underwent PCI. The GRACE score and HbA1c content 
were determined on admission. Correlation was analyzed by Spearman’s rank correlation. Cumulative MACE curve 
was calculated using the Kaplan–Meier method. Multivariate Cox regression was used to identify predictors of MACEs. 
Additionally, the predictive value of HbA1c content alone and combined with GRACE score was estimated by the 
area under the receiver‑operating characteristic curve (AUC), continuous net reclassification improvement (NRI) and 
integrated discrimination improvement (IDI).
Results: During a median of 42.3 months (interquartile range 39.3–44.2 months), 16 (2.9 %) were lost to follow‑up, 
and patients experienced 69 (12.9 %) MACEs: 51 (9.6 %) all‑cause deaths and 18 (3.4 %) nonfatal myocardial infarction 
cases. The GRACE score was positively associated with HbA1c content. Multivariate Cox analysis showed that both 
GRACE score and HbA1c content were independent predictors of MACEs (hazard ratio 1.030; 95 % CI 1.020–1.040; 
p < 0.001; 3.530; 95 % CI 1.927–6.466; p < 0.001, respectively). Furthermore, Kaplan–Meier analysis demonstrated 
increased risk of MACEs with increasing HbA1c content (log‑rank 33.906, p < 0.001). Adjustment of the GRACE risk 
estimate by HbA1c improved the predictive value of the GRACE score [increase in AUC from 0.75 for the GRACE score 
to 0.80 for the GRACE score plus HbA1c, p = 0.012; IDI = 0.055, p < 0.001; NRI (>0) = 0.70, p < 0.001].
Conclusions: HbA1c content is positively associated with GRACE risk score and their combination further improved 
the risk stratification for ACS patients without DM undergoing PCI.
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Background
Patients with acute coronary syndrome (ACS) are diverse 
in terms of clinical presentation and risk of death or dis-
ability. Accurate management decisions with comprehen-
sive evaluation may improve the outcomes of patients at 
high risk. To identify high-risk patients, current guide-
lines recommend a standardized approach involving 
validated scoring systems such as the Global Registry of 
Acute Coronary Events (GRACE) score [1–3]. Although 
the GRACE risk score has been validated, the score does 
not include measurement of important biomarkers. 
Therefore, whether combining other biomarkers with the 
GRACE score can provide a more accurate risk estima-
tion in ACS needs to be explored.
Long-term glycometabolic disorder implies high risk 
for cardiovascular disease [4, 5]. Glycosylated hemo-
globin (HbA1c) is a well-known biomarker of long-term 
glycometabolic state and is minimally affected by stress 
during ACS. Previous research found elevated HbA1c 
content related to increased risk of cardiovascular events 
[6–8].
In the present study, we investigated the predictive 
value of HbA1c content and GRACE score individually 
for major adverse cardiac events (MACEs) in patients 
with ACS but without diabetes mellitus (DM) undergo-
ing PCI and the potential incremental prognostic value of 
HbA1c content added to GRACE score.
Methods
Study cohort
We performed a single-center, observational study of 
consecutive non-diabetes patients with ACS performed 
PCI in the First Affiliated Hospital of Medical College 
of Xi’an Jiaotong University from December 2010 to 
December 2011, which included unstable angina, non-
ST-segment elevation myocardial infarction (NSTEMI), 
and ST-segment elevation MI (STEMI).
They all performed PCI using standard techniques 
after Qualitative and quantitative coronary angio-
graphic analyses. All procedural decisions, including 
device selection and adjunctive pharmacotherapy, were 
made at the discretion of experienced interventional 
cardiologists according to 2007 focused update of the 
ACC/AHA/SCAI 2005 guideline update for percutane-
ous coronary intervention [9]. The diagnostic criteria of 
DM were: HbA1c ≥6.5  %, FPG ≥7.0  mmol/L, 2-h PG 
≥11.1  mmol/L according to 2010 ADA Diagnosis and 
classification of diabetes mellitus [10].
Exclusion criteria were history of DM, treatment with 
diabetes drugs, HbA1c content ≥6.5 % on admission, no 
treatment with PCI, advanced liver disease, renal failure, 
cancer, valvular heart disease, stroke, idiopathic dilated 
or hypertrophic cardiomyopathy, peripheral arterial 
disease, pregnancy, receiving anti-inflammatory drugs, 
acute or chronic infections or autoimmune disease, and 
blood or thyroid disease.
The study complied with the Declaration of Helsinki 
and was approved by the ethics committee of the hos-
pital. Written informed consent was obtained from all 
patients.
Demographic and clinical data
Main demographic data, cardiovascular risk factors and 
cardiovascular drugs received were obtained from medi-
cal records. Current smokers were defined as having 
smoked more than 100 cigarettes during their lifetime 
and still smoking in the past 30 days. Hypertension was 
defined as resting blood pressure  ≥140/90  mmHg at 
two different visits or receiving hypertension drugs. Pre-
vious MI was based on a history of acute MI (AMI) or 
with signs of an infarction outside the area of the index 
infarction.
Blood samples
Peripheral blood was sampled from patients in a fasting 
state the morning following the admission day. Venous 
plasma concentrations of glucose, lipids, lipoproteins, 
serum creatinine, N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP), white blood cell, platelet count (PLT), 
Neutrophile count, Monocyte count and HbA1c content 
(normal values 4–6 %) were determined in the biochem-
istry department using standard biochemical techniques 
for the hospital. We calculated estimated glomerular fil-
tration rate as (ml min−1 1.73 m−2) = 194 × (serum cre-
atinine)−1.094 × (age)−0.287(× 0.739 if female).
They all performed Echocardiography for left ventricle 
function through left ventricle ejection fraction (LVEF).
Calculation of GRACE risk score
The GRACE risk prediction tool was previously described 
[11]. The score is derived from several variables (age, 
heart rate, systolic blood pressure, creatinine level, con-
gestive heart failure, in-hospital percutaneous coronary 
intervention, in-hospital coronary aortic bypass graft-
ing, history of MI, ST-segment depression, and elevated 
cardiac enzyme/marker levels) and calculated for each 
patient. The GRACE risk score was originally designed to 
predict post-discharge 6  month mortality and had been 
shown to provide good discrimination of mortality up to 
4 years after an ischemic event [12–14].
Outcomes and follow‑up
All-cause death and nonfatal MI were defined as MACEs. 
All patients were followed up by interview or telephone 
in our hospital, and the end of follow-up was the date 
of the first MACE occurrence obtained by reviewing 
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hospital records. Some patients were followed up until 
December 2014.
Statistical analysis
Data were analyzed by use of SPSS 19.0 for Windows 
(SPSS Inc., Chicago, IL, USA). Continuous variables 
were expressed as mean ± SD. Categorical variables were 
expressed as frequency and percentage. The Kolmogo-
rov–Smirnov test was used to assess normal distribution 
of quantitative variables. Independent samples t test was 
used to compare two groups, and categorical variables 
were compared by Chi square test. One-way ANOVA 
was used to compare multiple groups. To limit the influ-
ence of extreme observations, NT-proBNP was natural 
logarithmically transformed to obtain Ln NT-proBNP. 
Correlation was analyzed by Spearman’s rank correlation. 
Univariate and multivariate survival analyses involved 
Cox regression analysis. To assess the prognostic value of 
HbA1c content, Kaplan–Meier survival curves were used. 
Additionally, the incremental predictive value resulting 
from adding HbA1c variable to GRACE risk score was 
analyzed in the validation set using several measures 
of improvement in discrimination: increase in the area 
under the receiver-operating characteristic (ROC) curve 
(AUC), as well as integrated discrimination improvement 
(IDI), and continuous net reclassification improvement 
(NRI). DeLong’s test was used to compare the AUC from 
each of models [15], which were analyzed by use of Med-
Calc Version 11.4.2.0. The IDI was equal to the increase 
in discrimination slope defined as the mean difference in 
predicted risks between those with and without events. 
The continuous NRI was a non-parametric analogue of 
the IDI and equals twice the difference in probabilities of 
upward reclassification for events minus for non-events 
[16], which were analyzed by use of SAS 9.2 (SAS Insti-
tute Inc., Cary, NC, USA).




During a median of 42.3  months (interquartile range 
39.3–44.2 months), 16 (2.9 %) were lost to follow-up. In 
the study, a total of 533 consecutive patients (a mean age 
of 59.96 ± 12.65 years, 67.7 % man) included 203 unsta-
ble angina, 95 NSTEMI and 235 STEMI, the HbA1c con-
tent in each type of ACS was respectively 5.588 ± 0.45 %, 
5.598  ±  0.51  %, 5.610  ±  0.45  %, in which there was 
no statistical differences (p  =  0.878). Among the 533 
patients, 69 (12.9 %) experienced a MACE, including 51 
(9.6 %) all-cause deaths and 18 (3.4 %) nonfatal myocar-
dial infarction cases. The event rate of each type of ACS 
was 9.85  % (20/203), 15.78  % (15/95), 14.46  % (34/235). 
All patients were segregated into three groups by ter-
tiles of baseline HbA1c content (≤5.4 %, 5.5–5.8 %, 5.9–
6.4 %). Baseline characteristics were shown in Additional 
file 1: Table S1: Patients in the higher HbA1c levels more 
often had a prior history of PCI, were lower ejection frac-
tion, eGFR level, as well as higher in Monocyte count and 
LnNT-ProBNP.
Clinical characteristics of patients with and without MACEs
Patients with MACEs were elderly, had more frequent 
prior history of hypertension, prior history of MI, prior 
history of PCI and were higher LnNT-ProBNP, PLT, 
monocyte count, GRACE score and HbA1c content as 
well as lower ejection fraction compared to patients with-
out MACEs (Table  1). We carried out the correlation 
analysis between the GRACE risk score and HbA1c levels 
as continuous variables and showed that GRACE score 
was positively correlated with HbA1c content (R = 0.192, 
p < 0.001).
HbA1c content as an independent predictor of MACE 
occurrence
On univariate Cox analysis, significant predictors of 
a MACE were age, hypertension, prior MI,prior PCI, 
LVEF, LnNT-ProBNP, PLT, monocyte count, HbA1c 
content and GRACE score (Table  2). On multivari-
ate Cox analysis, HbA1c content was a significant and 
independent predictor of a MACE [hazard ratio (HR) 
3.530; 95  % confidence interval (95  % CI) 1.927–6.466; 
p  <  0.001] as was GRACE score (HR 1.030; 95  % CI 
1.020–1.0403; p < 0.001) (Table 3). The cumulative risk 
of a MACE generally increased with elevated HbA1c 
content by Kaplan–Meier analysis (log-rank 33.906, 
p < 0.001; Fig. 1).
Effect of HbA1c content and GRACE score combined 
on MACE occurrence
Since both HbA1c content and GRACE score were inde-
pendent risk factors of a MACE, we assessed the effect 
of their combination on predicting long-term risk of 
MACE occurrence. The AUC increased from 0.75 (95 % 
CI 0.69–0.82) for GRACE score alone to 0.80 (95  % CI 
0.75–0.85) for GRACE score adjustment by HbA1c 
content (difference in the AUCs, 0.05; z  value 2.521, 
p = 0.012) (Fig. 2). Addition of HbA1c content improved 
GRACE score alone model discrimination, which was 
confirmed by the IDI and the continuous, category-free 
NRI (>0). The IDI for HbA1c content was 0.055 (95 % CI 
0.035–0.075, P < 0.001), suggesting further average sepa-
ration of events from non-events by the HbA1c; the NRI 
(>0) for HbA1c content was 0.70, (95  % CI 0.47–0.94, 
P < 0.001), with events contributing 0.42 and non-events 
0.28 (Table  4), showing that the HbA1c content led to 
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a significant net reclassification of patients, risk in the 
appropriate directions.
Discussion
Management decisions in ACS should be based on risk 
stratification of patients. The GRACE score provides 
validated prognostic information for MACEs in ACS 
patients [12, 14]. In accordance with previous research 
results, the GRACE score could independently predict a 
MACE in our ACS patients without DM undergoing PCI. 
However, the AUC with the GRACE score alone was only 
0.75, which might be due to some potential risk factors 
not fully captured by the scoring system. Growing epi-
demiological evidence supports that HbA1c content in 
the general population and in patients with and without 
diabetes is an independent risk factor of cardiovascular 
events including MI [6, 8, 17]. However, HbA1c con-
tent has not been considered with the GRACE scoring 
Table 1 Characteristics of  non-DM patients with  ACS undergoing PCI with  or without  major adverse cardiac events 
(MACEs)
Data are mean ± SD or n (%)
BMI body mass index, Prior MI prior myocardial infarction, Prior PCI prior percutaneous coronary intervention, SBP systolic blood pressure, DBP diastolic blood pressure, 
eGFR estimated glomerular filtration rate, FBS fasting blood sugar, TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density 
lipoprotein cholesterol, Apo-A1 apolipoprotein A1, Apo-B apolipoprotein B, NT-proBNP N-terminal pro-B-type natriuretic peptide, PLT platelets, LVEF left ventricle 
ejection fraction, WBC white blood cell count, ACEI angiotensin-converting enzyme inhibition, ARB angiotensin receptor blocker, HbA1c hemoglobin A1c, GRACE score 
Global Registry of Acute Coronary Events (GRACE) score
Variable All patients (n = 533) With MACE (n = 69) Without MACE (n = 464) p value
Age (year) 59.96 ± 12.65 64.58 ± 11.43 59.27 ± 12.69 0.001
Sex
 Male 361 (67.7) 47 (68.1) 314 (67.7) 0.941
BMI (kg/m2) 24.11 ± 2.70 24.60 ± 2.96 24.04 ± 2.65 0.111
Hypertension 195 (36.6) 40 (58.0) 155 (33.4) <0.001
Smoking 333 (62.5) 48 (69.6) 285 (61.4) 0.192
Prior MI 37 (6.9) 13 (18.8) 24 (5.2) <0.001
Prior PCI 24 (4.5) 7 (10.1) 17(3.7) 0.015
DBP (mmHg) 77.94 ± 13.00 77.88 ± 12.40 77.95 ± 13.11 0.967
SBP (mmHg) 125.53 ± 20.02 126.35 ± 21.78 125.41 ± 19.77 0.716
Heart rate (bpm) 75.36 ± 13.27 77.12 ± 13.50 75.10 ± 13.24 0.240
eGFR (mL min−1 1.73 m−2) 88.60 ± 35.50 87.05 ± 37.31 88.83 ± 35.26 0.697
FBS (mmol/L) 6.37 ± 1.82 6.28 ± 1.35 6.39 ± 1.88 0.652
TC (mmol/L) 3.92 ± 1.08 3.94 ± 0.92 3.92 ± 1.10 0.926
TG (mmol/L) 1.62 ± 1.00 1.47 ± 1.07 1.65 ± 0.99 0.171
HDL (mmol/L) 1.02 ± 0.25 1.04 ± 0.26 1.02 ± 0.25 0.541
LDL (mmol/L) 2.28 ± 0.74 2.30 ± 0.75 2.27 ± 0.74 0.774
Apo A1 (g/L) 1.08 ± 0.18 1.08 ± 0.22 1. 08 ± 0.18 0.894
Apo B (g/L) 0.77 ± 0.23 0.76 ± 0.22 0.77 ± 0.23 0.904
LVEF (%) 54.26 ± 12.34 49.68 ± 12.23 54.94 ± 12.15 0.001
NT‑proBNP (pg/mL) 5.86 ± 1.60 6.30 ± 1.82 5.79 ± 1.56 0.013
PLT count (109/L) 192.81 ± 68.17 212.67 ± 82.73 189.86 ± 65.32 0.009
WBC count (109/L) 8.05 ± 3.23 8.38 ± 3.56 8.00 ± 3.18 0.366
Monocyte count (109/L) 0.57 ± 0.32 0.65 ± 0.45 0.55 ± 0.30 0.021
Neutrophile count (109/L) 5.92 ± 3.14 6.36 ± 3.21 5.85 ± 3.13 0.213
HbA1c content (%) 5.60 ± 0.46 5.90 ± 0.33 5.56 ± 0.46 <0.001
GRACE score 110.47 ± 27.13 131.45 ± 24.40 107.35 ± 26.13 <0.001
Medication at discharge
 Aspirin 524 (98.3) 66 (95.7) 458 (98.7) 0.066
 Clopidogrel 527 (98.9) 68 (98.5) 459 (98.9) 0.785
 Statins 430 (80.7) 58 (84.1) 372 (80.2) 0.446
 ACEI/ARB 389 (73.0) 46 (66.7) 343 (73.9) 0.205
 β‑blockers 347 (65.1) 42 (60.9) 305 (65.7) 0.429
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system in previous research. In our patients, the GRACE 
score increased with increasing HbA1c content at base-
line, and the 2 variables were correlated. Moreover, the 
GRACE score adjustment by HbA1c content on admis-
sion enhanced the predictive value for ACS patients 
without DM undergoing PCI (AUC increased from 0.75 
for GRACE score alone to 0.80 for GRACE score plus 
HbA1c).To better assess the improvement in discrimi-
nation of GRACE score adjustment by HbA1c variable, 
we used new statistical metrics [IDI and a category-
free, continuous NRI (>0)], and IDI for HbA1c showed 
further average separation of events from non-events 
by the HbA1c; Using the a category-free, continuous 
NRI (>0),we fund that a net 28  % of the patients with-
out events were reclassified into lower risk and that a 
net 42  % of patients with events were reclassified into 
higher risk. The category-free, continuous NRI (>0) thus 
Table 2 Univariate Cox analysis for MACEs
HR hazard ratio, 95 % CI 95 % confidence interval
Variable HR 95 % CI p value
Age (per 1 year) 1.032 1.012–1.052 0.001
Male (vs. female) 0.910 0.480–1.725 0.772
BMI (per 1 kg/m2) 1.071 0.984–1.166 0.111
Hypertension 2.571 1.594–4.148 <0.001
Smoking 1.438 0.861–2.402 0.165
Prior MI 3.454 1.888–6.319 <0.001
Prior PCI 2.839 1.299–6.206 0.009
DBP (per 1 mmHg) 1.000 0.982–1.018 0.976
SBP (per 1 mmHg) 1.002 0.991–1.014 0.716
Heart rate (per 1 mmHg) 1.010 0.993–1.026 0.240
eGFR (per 1 mL min−1 1.73 m−2) 0.998 0.992–1.005 0.647
FBS (per 1 mmol/L) 0.976 0.856–1.112 0.712
TC (per 1 mmol/L) 1.013 0.820–1.252 0.903
TG (per 1 mmol/L) 0.787 0.566–1.094 0.153
HDL (per 1 mmol/L) 1.355 0.543–3.380 0.515
LDL (per 1 mmol/L) 1.048 0.767–1.432 0.766
Apo A1 (per 1 g/L) 0.926 0.248–3.451 0.908
Apo B (per 1 g/L) 0.955 0.338–2.697 0.931
LVEF (per 1 %) 0.965 0.945–0.985 0.001
NT‑proBNP (per 1 ln unit) 1.236 1.052–1.451 0.010
PLT count (per 109/L) 1.004 1.001–1.006 0.006
WBC count (per 109/L) 1.035 0.966–1.109 0.326
Monocyte count (per 109/L) 2.141 1.189–3.855 0.011
Neutrophile count (per 109/L) 1.046 0.976–1.120 0.202
HbA1c content (per 1 %) 5.342 2.968–9.613 <0.001
GRACE score (per 1) 1.033 1.024–1.043 <0.001
Table 3 Multivariate Cox analysis for MACEs
HR hazard ratio, 95 % CI 95 % confidence interval
Variable HR 95 % CI p value
HbA1c (per 1 %) 3.530 1.927–6.466 <0.001
GRACE score (per 1) 1.030 1.020–1.040 <0.001
Hypertension 1.932 1.185–3.148 0.008
Prior MI 2.372 1.284–4.328 0.006
LVEF (per 1 %) 0.972 0.952–0.992 0.006
PLT (per 109/L) 1.116 1.023–1.218 0.013
Fig. 1 Kaplan–Meier analysis of major adverse cardiac events 
(MACEs) based on hemoglobin A1c (HbA1c) content. The 533 
patients were divided by tertiles of HbA1c content: ≤5.4 %, 5.5–5.8 %, 
and 5.9–6.4 %. Risk of a MACE increased with increasing tertile of 
HbA1c content (log‑rank test 33.906, p < 0.001)
Fig. 2 Receiver operating characteristic (ROC) curve analysis. The 
addition of HbA1c content to the GRACE score as continuous vari‑
ables could improve the predictive power for long‑term MACEs (area 
under the ROC curve for GRACE score alone, 0.75; combined with 
HbA1c content, 0.80; z value 2.521, p = 0.012)
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reached an impressive 0.70, which suggested that the 
HbA1c content led to a significant net reclassification of 
patients, risk in the appropriate directions.
In the present study, the long-term event rate seems 
low compared previous researches. It may attribute to 
followed reasons. Firstly, the enrolled patients were non-
DM, which were lower in the cardiovascular events rate 
than that in patients with diabetic mellitus, especially 
in the patients of poor nocturnal glycemic control [18]. 
Secondly, Recent some reports have shown ethnic dif-
ferences effect the MACE occurrence rate after PCI not 
only between African Americans and whites [19, 20],but 
also in Asian subpopulations, such as compared to 
Indian, Chinese patients have lower Major Adverse Car-
diovascular Events [21–23].  In addition, our results was 
comparable compared with the MACE rate documented 
by Clinical Pathways for Acute Coronary Syndromes in 
China (CPACS) study [24, 25].
Although some research had found that higher level of 
admission glucose predict a worse prognosis including 
mortality and MI in ACS patients [26–28], recent stud-
ies showed that the prediction value of admission glu-
cose was not improved by combining GRACE score [29]. 
As different from admission glucose, HbA1c is an indi-
cator of general glycometabolic state and is minimally 
affected by acute stress and also acute glucose manage-
ment. Increased HbA1c content was not only showed as 
a indictor of complications including ACS [30] but also 
a predictor of long-term survival in ACS patients with 
and without DM [31–33]. Whether the HbA1c con-
tent in ACS patients without DM undergoing PCI could 
be an independent predictor of cardiovascular events 
is uncertain. In our study, HbA1c content at baseline 
was higher in patients with than without a MACE, and 
HbA1c content could independently predict a long-
term MACE in ACS patients without DM undergoing 
PCI. Furthermore, we found that the predictive value 
on MACE of adding HbA1c on the top of GRACE score 
system.
Researches have found that C-reactive protein [34], 
NT-proBNP [35], erythrocyte fatty acids [36], growth dif-
ferentiation factor-15 [37], cystatin C [38], dikkopf [39], 
RDW/PDW [40], high-sensitivity troponin [41], mean 
platelet volume(MPV) [42] and other factors add value 
to a scoring system for predicting adverse cardiovascular 
events after ACS. We found that GRACE score and base-
line HbA1c content were positively correlated, and their 
combination improved the predictive value. Whether this 
combination can improve the outcome of ACS patients 
with DM needs further comprehensive investigation in 
clinical practice.
Limitations
The number of patients in the cohort was relatively small. 
Therefore, these findings need to be verified by multi-
center and larger cohort studies. In addition, this study 
was limited to Chinese subjects, so conclusions for other 
ethnic groups are cautioned.
Conclusions
HbA1c content measured in ACS patients without DM 
undergoing PCI could predict a MACE and was posi-
tively related with GRACE score. The combination of 
the two factors may improve on risk stratification of ACS 
patients without DM undergoing PCI.
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